Foghorn Therapeutics (FHTX) Net Equity Issued and Repurchased (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Net Equity Issued and Repurchased came in at $50.0 million in Q1 2026, up 19.26% quarter-over-quarter from $41.9 million in Q3 2020.
Foghorn Therapeutics (FHTX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $50.0 million for Q1 2026.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $50.0 million in Q1 2026; TTM through Mar 2026 was $50.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $103.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $50.0 million in Q1 2026 per FHTX's latest filing, from $41.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $50.0 million in Q1 2026 and bottomed at $50.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | 50.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.00 Mn |
| Mar 31, 2026 | 50.00 Mn |
| Sep 30, 2020 | 41.93 Mn |
| Sep 30, 2020 | 41.93 Mn |